CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children
CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children
Recruiting · NCT04510051 · Registry updated 2026-03-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children | Neoplasms by Site, brain cancer, brain disorder, central nervous system cancer, central nervous system disorder, neoplasm, nervous system disorder | Recruiting | Phase 1 | 2026-03-05 | NCT04510051 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| City of Hope Medical Center | 347 |
| National Cancer Institute (NCI) | 3015 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| C.S. MOTT Children's Hospital, University of Michigan | Ann Arbor | United States | 2 |
| Children's Hospital Los Angeles | Los Angeles | United States | 226 |
| City of Hope Medical Center | Duarte | United States | 313 |